United States Patent 9,669,024: Hydrocodone Extended-Release Dosage Form Patent Scope and Landscape

U.S. Patent No. 9,669,024 protects oral extended-release hydrocodone dosage forms defined primarily by pharmacokinetic performance rather than by a single formulation recipe. The patent requires hydrocodone to be the only active drug and covers tablets or capsules that maintain specified plasma concentrations for at least 12 hours. Its narrower claims add 24-hour release, polymer matrices, hydroxypropylcellulose or hydroxypropylmethylcellulose, polyalkylene glycol excipients, 15 mg hydrocodone bitartrate, and C12/Cmax pharmacokinetic ratios.

The patent is associated with Purdue Pharma’s extended-release hydrocodone product Hysingla ER. The principal commercial and legal risks concern whether a competing product reproduces the claimed plasma profile, whether the patent is listed for the relevant FDA-approved product, and whether an abbreviated new drug application includes a Paragraph IV certification.

What drug and dosage form does U.S. Patent 9,669,024 protect?

The patent protects hydrocodone-only oral dosage forms. It does not cover combination products containing acetaminophen or another active pharmaceutical ingredient.

The broadest claim architecture requires:

Limitation	Claims principally affected
Hydrocodone or pharmaceutically acceptable salt	1, 24, 31
Hydrocodone is the only drug	1, 24, 31
Oral dosage form	1, 24, 31
Tablet or capsule	1, 31; claim 25 narrows claim 24 to tablet
Controlled release for approximately 8 to 24 hours	2, 24
At least approximately 8 ng/mL at about eight hours	1, 24, 31
At least approximately 5 ng/mL at 12 hours	1, 24
At least 3.93 ng/mL at 12 hours	31
24-hour controlled release	2, 3
1% to 80% excipient or polymer by weight	6, 24
Hydroxyalkylcellulose	8-10
Polyalkylene glycol	11
Cmax increases linearly with dosage strength	12
C12/Cmax ratio of 0.55 to 0.85	13, 27
C12/Cmax ratio of 0.55 to 0.65	14, 16, 19
C12/Cmax ratio of 0.65 to 0.85	15, 17, 20
Relatively flat plasma profile	18, 28
15 mg hydrocodone bitartrate	32

The central inventive concept is an extended-release hydrocodone product that reaches a clinically meaningful concentration early and maintains exposure through the 12-hour interval without exceeding toxic concentrations. The claim set therefore combines composition, dosage-form, release-duration, and pharmacokinetic limitations (U.S. Patent No. 9,669,024, 2017).

What are the independent claims in Patent 9,669,024?

Claims 1, 24, and 31 are the independent claims supplied for analysis.

Claim 1: broad PK-defined tablet or capsule

Claim 1 requires an oral tablet or capsule in which:

Hydrocodone, or its pharmaceutically acceptable salt, is the only drug.
Release occurs over approximately 12 hours or longer.
Hydrocodone plasma concentration is at least approximately 8 ng/mL at about eight hours.
Plasma concentration is approximately 5 ng/mL or greater at 12 hours.
Concentrations remain in the therapeutic range and below toxic concentrations.

Claims 2 through 23 narrow claim 1. The most commercially important limitations are 24-hour release, tablet form, an early concentration of at least 8 ng/mL at two hours, polymer content, and C12/Cmax ratios.

Claim 24: excipient-based independent claim

Claim 24 requires:

Hydrocodone as the only drug;
an excipient comprising 1% to 80% by weight;
controlled release over approximately 8 to 24 hours;
at least approximately 8 ng/mL at about eight hours; and
at least approximately 5 ng/mL at 12 hours.

Unlike claims 1 and 31, claim 24 does not make tablet or capsule form an express limitation. Claim 25 narrows it to a tablet. This creates a potentially broader claim category for an oral controlled-release dosage form containing an excipient, although the concentration limitations remain substantial infringement barriers.

Claim 31: lower 12-hour concentration threshold

Claim 31 resembles claim 1 but reduces the 12-hour concentration requirement from approximately 5 ng/mL to 3.93 ng/mL. Claim 32 narrows claim 31 to a dosage form containing 15 mg of hydrocodone bitartrate.

This claim is strategically important because a product may fall below the approximately 5 ng/mL threshold in claim 1 while still meeting the express 3.93 ng/mL threshold in claim 31.

How strong are the patent claims?

The patent has a mixed strength profile. The composition and dosage-form limitations are conventional for extended-release opioid technology. The stronger protection comes from the combined pharmacokinetic limitations, particularly when linked to a specific release matrix and dose.

Claim-strength assessment

Claim group	Relative strength	Primary reason
Claims 1-4	Moderate	Broad product and PK requirements; vulnerable to prior-art ER hydrocodone products
Claims 5-11	Moderate to strong	Adds identifiable polymer and excipient limitations
Claims 12-23	Stronger against direct copying	Requires specific PK relationships and fed/fasted testing conditions
Claims 24-26	Moderate	Independent excipient claim with broad dosage-form language
Claims 27-30	Stronger	Adds C12/Cmax and profile limitations
Claims 31-32	Moderate to strong	Lower 12-hour threshold broadens coverage, while 15 mg narrows claim 32

The principal validity issues would likely involve anticipation, obviousness, enablement, written description, and indefiniteness.

Anticipation and obviousness

An earlier extended-release hydrocodone product could anticipate the claims only if a single prior-art reference disclosed all required structural and pharmacokinetic limitations. A reference showing hydrocodone in a polymer matrix would not necessarily anticipate a claim requiring:

8 ng/mL at eight hours;
5 ng/mL or 3.93 ng/mL at 12 hours;
a C12/Cmax ratio between 0.55 and 0.85; and
hydrocodone as the only drug.

Obviousness remains a more substantial risk. Prior art combining hydrocodone, opioid extended-release matrices, hydroxypropylmethylcellulose, and routine pharmacokinetic optimization could support an obviousness challenge. The patent holder would argue that the claimed profile, food-condition performance, dose proportionality, and relatively flat exposure were not predictable from the prior art.

Indefiniteness and enablement

Several terms create potential claim-construction disputes:

“about 12 hours or longer”
“therapeutic range”
“below toxic concentrations”
“relatively flat”
“at about 8 hours”
“at 12 hours”
“first oral administration”
“fed human” and “fasted human”

The numeric limitations are more objective than the therapeutic-range language. A court would likely rely on the specification, clinical protocols, and ordinary pharmacokinetic practice to construe the terms. The inclusion of fed and fasted conditions in dependent claims can create evidentiary disputes over study design, food composition, sampling time, and population averaging.

What formulation technology is protected?

The dependent claims identify a hydrophilic polymer matrix formulation.

Polymer matrix protection

Claims 5 through 10 cover tablets containing a pharmaceutically acceptable polymer in an amount potentially ranging from 1% to 80% by weight. The polymer may be:

hydroxyalkylcellulose;
hydroxypropylcellulose; or
hydroxypropylmethylcellulose.

Hydroxypropylmethylcellulose, commonly abbreviated HPMC, is the narrowest polymer category expressly identified in claim 10.

The claims do not require a particular polymer grade, viscosity, particle size, compression force, tablet hardness, or coating system in the text supplied. Those details may appear in the specification, but they are not express limitations of the cited claims.

Excipient protection

Claim 7 adds an excipient with a melting point from 30°C to approximately 200°C. Claim 11 narrows the excipient to a polyalkylene glycol. This language may capture polyethylene glycol or related materials, depending on the intrinsic evidence and claim construction.

The 1% to 80% weight range is broad. A competitor using a polymer or excipient outside that range could avoid the literal limitation of claims 6 or 24, although other claims may remain relevant.

What pharmacokinetic profile does the patent require?

The patent is unusually dependent on measured plasma exposure.

Required concentration profile

The principal concentration requirements are:

Time after administration	Required concentration
Approximately 2 hours	At least 8 ng/mL under claims 4 and 26
Approximately 8 hours	At least 8 ng/mL under claims 1, 24, and 31
12 hours	At least approximately 5 ng/mL under claims 1 and 24
12 hours	At least 3.93 ng/mL under claim 31

Claims 13 through 17 and 27 through 29 add the C12/Cmax ratio. The claimed range is 0.55 to 0.85, with narrower subranges of 0.55 to 0.65 and 0.65 to 0.85.

A product with a high early peak followed by rapid decline may fail the ratio limitation even if it qualifies as an extended-release product. Conversely, a product with a relatively low peak and sustained concentration may satisfy the ratio limitation but fail the eight-hour or 12-hour absolute concentration thresholds.

Testing conditions

Claims 16, 17, and 22 specify fasted humans. Claims 19 through 21 and 23 specify fed humans. These limitations can materially affect infringement analysis because food can change the rate and extent of hydrocodone absorption.

For an ANDA product, the applicant’s bioequivalence studies, dissolution data, comparative PK data, and batch records would be central evidence. The relevant question is not whether the label uses the same language as the patent. It is whether the product, when administered under the claimed conditions, meets each limitation.

When does U.S. Patent 9,669,024 expire?

The patent’s commonly reported nominal expiration date is June 29, 2027, based on the patent family’s June 29, 2007 priority date and the applicable patent-term record. The operative date must be determined from the USPTO patent-term calculation, including any patent-term adjustment, terminal disclaimer, pediatric exclusivity, or patent-term extension. The patent grant date was June 6, 2017 (U.S. Patent and Trademark Office, 2017).

The patent is therefore a late-decade exclusivity asset rather than a long-duration platform patent. Any FDA regulatory exclusivity associated with the original hydrocodone product would be separate from the patent term.

What is the FDA and Orange Book status?

Hysingla ER is an FDA-approved extended-release hydrocodone bitartrate product indicated for the management of pain severe enough to require a daily, around-the-clock, long-term opioid treatment for which alternative treatments are inadequate (FDA, 2023).

The product is a hydrocodone-only extended-release tablet, which aligns with the core product concept in claims 1, 2, 3, 25, and 32. Hysingla ER is also identified by FDA as having abuse-deterrent properties based on its formulation and labeling. Abuse-deterrence does not itself establish infringement of Patent 9,669,024, because the cited claims focus on hydrocodone content, release duration, excipients, and PK outcomes.

The Orange Book is the controlling source for current listed patents, use codes, and exclusivity information. Patent 9,669,024 should be evaluated against the current FDA publication rather than inferred solely from the patent document, because Orange Book listings can change through delisting, corrections, or product-specific updates (FDA, 2024).

What Paragraph IV risks exist for generic hydrocodone ER products?

A generic applicant seeking approval before patent expiry could certify under Paragraph IV that the patent is invalid, unenforceable, or not infringed. A Paragraph IV notice would create potential litigation under the Hatch-Waxman Act and could trigger a statutory 30-month stay of approval if suit were filed within the applicable period (21 U.S.C. § 355(j)(5)(B)(iii), 2024).

The principal Paragraph IV strategies would include:

Noninfringement based on PK values. The applicant could design a product that does not reach 8 ng/mL at eight hours, does not reach the applicable 12-hour threshold, or falls outside the C12/Cmax range.
Formulation design-around. A product could use a non-cellulosic matrix, a multiparticulate system, a coating-controlled system, or an excipient concentration outside the claimed range.
Validity challenge. The applicant could assert that the claimed PK profile was predictable from prior-art extended-release opioid formulations.
Claim-construction challenge. The applicant could contest “about,” “therapeutic range,” “toxic concentrations,” “relatively flat,” and the fed/fasted population requirements.
Patent-listing challenge. The applicant could dispute whether the patent claims the approved drug or an approved method of use sufficiently for Orange Book listing.

The patent’s concentration limitations make a conventional “same active ingredient, same strength, same release duration” generic design potentially risky if the product is bioequivalent to Hysingla ER.

Which companies are challenging the patent?

The supplied claim text does not establish a current Paragraph IV filer, litigation defendant, settlement, or licensee. Patent ownership, FDA listing, ANDA certifications, and docket activity are separate records and cannot be determined from the claims alone.

The relevant competitive set includes generic manufacturers capable of developing hydrocodone bitartrate extended-release tablets and branded opioid manufacturers with controlled-release matrix technology. A definitive challenger analysis requires matching current FDA ANDA records and federal-court docket data to the Orange Book listing for the reference product.

What litigation and settlement issues matter?

The likely litigation issues are product-specific rather than abstract:

whether the accused product meets the claimed plasma concentrations;
whether infringement can be proved from ANDA data or must await commercial testing;
whether the claims are construed to require all listed fed or fasted conditions;
whether the patent claims the approved Hysingla ER product for Orange Book purposes;
whether a terminal disclaimer limits enforceable term; and
whether a settlement permits an agreed generic launch before the nominal expiry date.

A settlement could establish a licensed entry date, supply arrangement, or authorized-generic structure. No settlement terms can be attributed to Patent 9,669,024 from the supplied claims.

How does Patent 9,669,024 compare with competing hydrocodone products?

Product category	Hydrocodone only?	Extended release?	Relevance to Patent 9,669,024
Hysingla ER	Yes	Yes	Closest branded product profile
Zohydro ER	Yes	Yes	Competing hydrocodone-only ER product; formulation and PK must be compared claim by claim
Hydrocodone/acetaminophen immediate-release products	No	Generally no	Usually outside the “only drug” limitations
Oxycodone ER products	No, different active ingredient	Yes	Prior-art and technology comparators, not literal hydrocodone products
Generic hydrocodone ER tablets	Yes	Yes	Highest direct infringement and Paragraph IV risk

The patent does not protect hydrocodone generally. It protects a defined extended-release performance profile and selected formulation implementations.

What commercial exposure does the patent create?

The commercial exposure is concentrated in hydrocodone-only extended-release tablets, particularly products matching Hysingla ER strengths and release behavior. The principal loss scenario is an early generic launch that is bioequivalent enough to meet the claims while avoiding or invalidating the patent.

Revenue exposure depends on:

Hysingla ER net sales during the remaining patent term;
the number of generic applicants;
the timing of Paragraph IV litigation;
any settlement entry date;
the availability of authorized-generic supply; and
the ability of a challenger to design around the PK limitations without losing FDA bioequivalence.

Because the patent expires in 2027 on the commonly reported term schedule, its value is primarily in protecting the remaining branded hydrocodone ER franchise and delaying interchangeable generic competition.

Key Takeaways

U.S. Patent 9,669,024 covers hydrocodone-only oral extended-release dosage forms, not hydrocodone combinations generally.
Claims 1, 24, and 31 are the principal independent claims.
The strongest practical limitations are the eight-hour and 12-hour plasma concentrations and the C12/Cmax ratio.
Claims 5 through 11 add hydrophilic polymer and excipient protection, including HPMC and polyalkylene glycol.
Claim 32 specifically covers a 15 mg hydrocodone bitartrate dosage form.
The commonly reported nominal expiration date is June 29, 2027, subject to the official USPTO term calculation.
A generic applicant’s principal design-around options are PK separation, alternative release technology, and non-cellulosic or differently proportioned excipients.
Hysingla ER is the closest commercial product to the claimed subject matter.
Paragraph IV risk depends on the current Orange Book listing, ANDA certifications, and litigation record, none of which are established by the claim text alone.
The patent is a product-and-performance patent, with claim strength concentrated in the combined PK limitations.

FAQs

Does Patent 9,669,024 cover immediate-release hydrocodone?

No. The claims require controlled or extended release over approximately 8 to 24 hours or 12 hours or longer.

Does the patent cover hydrocodone-acetaminophen products?

Generally no. The independent claims require hydrocodone to be the only drug in the dosage form.

Can a generic avoid infringement by using a different polymer?

Potentially. A different polymer may avoid claims 8 through 10, but the generic could still face claims 1, 24, 27, or 31 if its dosage form meets the claimed PK thresholds.

Is a 12-hour product automatically covered?

No. Duration alone is insufficient. The product must also satisfy the applicable plasma concentration limitations and, for some claims, the C12/Cmax ratio.

Does abuse-deterrent labeling prove infringement?

No. Abuse-deterrent status is a regulatory and product-design characteristic. Infringement depends on satisfaction of the patent’s claim limitations.

References

Food and Drug Administration. (2023). Hysingla ER prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,669,024: Hydrocodone formulations. U.S. Department of Commerce.
21 U.S.C. § 355(j)(5)(B)(iii) (2024).
35 U.S.C. §§ 154, 156 (2024).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	526950	⤷ Start Trial
Australia	1446501	⤷ Start Trial
Australia	2003262463	⤷ Start Trial
Australia	764453	⤷ Start Trial
Brazil	0015284	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,669,024

Summary for Patent: 9,669,024